{"nct_id":"NCT01968551","title":"Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults","status":"COMPLETED","status_verified_date":"2017-07","start_date":"2013-09-03","start_date_type":"ACTUAL","primary_completion_date":"2015-07-21","primary_completion_date_type":"ACTUAL","completion_date":"2016-07-09","completion_date_type":"ACTUAL","phases":["PHASE3"],"tickers":["GILD"]}